

DOI: [10.15419/bmrat.v5i5.439](https://doi.org/10.15419/bmrat.v5i5.439)

Letter to Editor



Article History:

Received: 8 March 2018

Accepted: 07 May 2018

Published: 15 May 2018

Keywords:

Lung cancer, Prevention, Statins

Author for correspondence:

Abdollah Mohammadian-Hafshejani

e-mail: amohamadii1361@gmail.com

The relationship between Statins and the risk of lung cancer

Hamid Salehiniya¹, Khadijah Allah Bakeshei², Fatemeh Allah Bakeshei³ and Abdollah Mohammadian-Hafshejani^{4,5}

¹Zabol University of Medical Sciences, Zabol, Iran

²Department of Social Medicine, School of Public Health, Dezful University of Medical Sciences, Dezful, Iran

³Student Research Committee, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴Department of Epidemiology and Biostatistics, School of Public Health, Shahrekord University of Medical Sciences, Shahrekord, Iran

⁵Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

1. Dear editor in chief

Lung cancer is the leading cause of death from cancer. There are annually around 1600000 of new cases and more than 1400000 deaths from this disease worldwide. Lung cancer accounted for 26% of death from cancer in females in the United States in 2012 and 29% of death from cancer in males [1]. Statins are known as the most commonly prescribed drugs worldwide. Statins are usually used as the cholesterol-lowering drugs. The recent studies have proved the benefits of Statins in reducing the mortality and incidence of cardiovascular disease and stroke [2].

Newman and Hulley conducted a review study on the relationship between fat reducing drugs and the risk of cancer. In this study, they found that Statins might increase the risk of cancer in recipients, and in fact, they suggested that Statins might be carcinogenic [3]. However, several observational and experimental studies indicated the beneficial and protective effects of Statins on the incidence of cancer [4,5]. The relationship between Statin use and the risk of lung cancer has been studied in a number of studies. However, results of these studies are controversial. In these circumstances, the meta-analytic studies can be useful and helpful in combining results of studies and confirming or rejecting the association between Statins and the risk of lung cancer. According to a meta-analytic research by Wang et al based on 20 experimental and observational studies, the relative risk (RR) of incidence of lung cancer was equal to $RR = 0.89$ (CI of 95%, 0.78-1.02) in the subjects who received Statins compared with the control group [6]. According to another meta-analytic study by Tan et al based on 19 studies on the relationship between Statin use and the risk of lung cancer, the risk of lung cancer in the Statin group was equal to $RR = 0.89$ (CI of 95%, 0.77-1.03) compared to the control group. In this study, the estimated relative risk was equal to $RR = 0.91$ (CI of 95%, 0.76-1.09) for randomized clinical trials (RCTs), $RR = 0.82$ (CI of 95%, 0.57-1.16) for case-control studies, and $RR = 0.94$ (CI of 95%, 0.82-1.07) for Cohort studies [7]. Consequently, according to results of meta-analysis studies, there is not significant association between Statins and the risk of lung cancer; therefore, the Statin use does not increase or decrease the risk of lung cancer.

2. Open Access

This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

3. List of abbreviations

CI: Confidence: Confidence Interval; LC: Lung Cancer; RCTs: Randomized Clinical Trials; RR: Relative Risk

4. Competing interests

The authors declare that no competing interests exist.

5. Ethics approval and consent to participate

Not to be applied

6. Funding

Not to be applied

7. Authors' contributions

All authors contributed to the design of the research, HS and FAB, extracted the data and summarized it. All authors drafted the first version. KAB and AMH edited the first draft. All authors reviewed, commented and approved the final draft.

8. Acknowledgements

Not to be applied

References

1. Rebecca S, Deepa N, Ahmedin J. 2012 Cancer statistics, 2012. *Ca Cancer J Clin* **62**, 10–29.
2. Baigent C. 2005 Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* **366**, 1267–1278.
3. Newman TB, Hulley SB et al.. 1996 Carcinogenicity of lipid-lowering drugs. *JAMA-Journal of the American Medical Association-US Edition* **275**, 55–60.
4. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S. 2002 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. *Neoplasia* **4**, 337–346.
5. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, Bitterman P. 1998 Lovastatin induces apoptosis in malignant mesothelioma cells. *American journal of respiratory and critical care medicine* **157**, 1616–1622.
6. Wang J, Li C, Tao H, Cheng Y, Han L, Li X, Hu Y. 2013 Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials. *PLoS one* **8**, e77950.
7. Tan M, Song X, Zhang G, Peng A, Li X, Li M, Liu Y, Wang C. 2013 Statins and the risk of lung cancer: a meta-analysis. *PLoS One* **8**, e57349.